Update date
31 Dec 2019
Shareable Research Card
ABUS - Arbutus Biopharma Corp Cash and Cash Equivalents, Period Increase (Decrease)
This metric view shows ABUS - Arbutus Biopharma Corp cash and cash equivalents, period increase (decrease) history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2019
- Latest reported value
- $5,143,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2019
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2019.
- Latest reported value on this page: $5,143,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Cash and Cash Equivalents, Period Increase (Decrease)
Latest reported cash and cash equivalents, period increase (decrease): $5,143,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2019
SEC-backed company facts were refreshed from filings filed on 13 May 2026.
Benchmark Context
How Cash and Cash Equivalents, Period Increase (Decrease) compares with peers
Arbutus Biopharma Corp is outside the visible top 120 companies for cash and cash equivalents, period increase (decrease) in the current sample.
Compared with
Compared with 120 companies reporting cash and cash equivalents, period increase (decrease) in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Cash and Cash Equivalents, Period Increase (Decrease) is up about 70% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2010 to 31 Mar 2022.
- Nearby companies in this sample: AT&T INC. and AbbVie Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Arbutus Biopharma Corp: Cash and Cash Equivalents, Period Increase (Decrease)
Latest period: 2019. Period end: 31 Dec 2019. Units: USD and CAD. Frequency: annual and quarterly.
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
Metric snapshot
- Latest value
- $5,143,000
- Coverage range
- 31 Dec 2010 - 31 Dec 2019
- Fact rows
- 32
What this metric tells you
- Shows reported cash and cash equivalents, period increase (decrease) over 31 Dec 2010 - 31 Dec 2019.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 32 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Cash and Cash Equivalents, Period Increase (Decrease) levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | AT&T INC. (t) | $44,710,000,000 | Year - 31 Dec 2017 | Open AT&T INC. Cash and Cash Equivalents, Period Increase (Decrease) |
| 2 | AbbVie Inc. (abbv) | $32,635,000,000 | Year - 31 Dec 2019 | Open AbbVie Inc. Cash and Cash Equivalents, Period Increase (Decrease) |
| 3 | BANK OF AMERICA CORP /DE/ (bac) | $19,970,000,000 | Year - 31 Dec 2018 | Open BANK OF AMERICA CORP /DE/ Cash and Cash Equivalents, Period Increase (Decrease) |
| 4 | DANAHER CORP /DE/ (dhr) | $19,124,500,000 | Year - 31 Dec 2019 | Open DANAHER CORP /DE/ Cash and Cash Equivalents, Period Increase (Decrease) |
| 5 | Apple Inc. (aapl) | $18,858,000,000 | Quarter - 29 Dec 2018 | Open Apple Inc. Cash and Cash Equivalents, Period Increase (Decrease) |
| 6 | Alibaba Group Holding Ltd (baba) | $8,860,000,000 | Year - 31 Mar 2018 | Open Alibaba Group Holding Ltd Cash and Cash Equivalents, Period Increase (Decrease) |
Metric Details
- Metric
- Cash and Cash Equivalents, Period Increase (Decrease) (CashAndCashEquivalentsPeriodIncreaseDecrease)
- Frequency coverage
- annual and quarterly
- Taxonomy
- us-gaap
- Units tracked
- USD and CAD
- History range
- 31 Dec 2010 - 31 Dec 2019
- Facts on this page
- 32
- Metric definition
-
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of...
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
How to read it
1 detail
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Cash and Cash Equivalents, Period Increase (Decrease), Annual (USD)
Cash and Cash Equivalents, Period Increase (Decrease), YoY Annual Change (%)
Cash and Cash Equivalents, Period Increase (Decrease), Trailing 12 Months (USD)
Cash and Cash Equivalents, Period Increase (Decrease), Quarterly (USD)
Cash and Cash Equivalents, Period Increase (Decrease), YoY Quarterly Change (%)
Cash and Cash Equivalents, Period Increase (Decrease), Annual (CAD)
Cash and Cash Equivalents, Period Increase (Decrease), YoY Annual Change (%)
Arbutus Biopharma Corp Annual Cash and Cash Equivalents, Period Increase (Decrease) (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2019 | $5,143,000 | +$12,207,000 | +70% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 05 Mar 2020 | 2019 | FY |
| 2018 | $17,350,000 | -$48,229,000 | -156% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 05 Mar 2020 | 2019 | FY |
| 2017 | $30,879,000 | +$174,245,000 | 01 Jan 2017 | 31 Dec 2017 | 10-K | 07 Mar 2019 | 2018 | FY | |
| 2016 | $143,366,000 | -$237,958,000 | -252% | 01 Jan 2016 | 31 Dec 2016 | 10-K | 16 Mar 2018 | 2017 | FY |
| 2015 | $94,592,000 | +$91,122,000 | +2626% | 01 Jan 2015 | 31 Dec 2015 | 10-K | 16 Mar 2018 | 2017 | FY |
| 2014 | $3,470,000 | -$18,223,000 | -84% | 01 Jan 2014 | 31 Dec 2014 | 10-K | 22 Mar 2017 | 2016 | FY |
| 2013 | $21,693,000 | -$16,300,000 | -43% | 01 Jan 2013 | 31 Dec 2013 | 10-K | 09 Mar 2016 | 2015 | FY |
| 2012 | $37,993,000 | +$41,374,920 | 01 Jan 2012 | 31 Dec 2012 | 10-K | 13 Mar 2015 | 2014 | FY | |
| 2011 | $3,381,920 | 01 Jan 2011 | 31 Dec 2011 | 10-K | 28 Mar 2014 | 2013 | FY |
Arbutus Biopharma Corp Quarterly Cash and Cash Equivalents, Period Increase (Decrease) (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2018 | $14,019,000 | $2,268,000 | +$3,371,000 | +60% | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 03 Aug 2018 | 2018 | Q2 |
| Q1 2018 | $17,390,000 | $41,831,000 | -$48,269,000 | -750% | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 04 May 2018 | 2018 | Q1 |
| Q4 2017 | $30,879,000 | $39,067,000 | +$42,284,000 | 01 Oct 2017 | 31 Dec 2017 | 10-K | 07 Mar 2019 | 2018 | FY | |
| Q3 2017 | $11,405,000 | $8,987,000 | +$7,353,000 | +45% | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 02 Nov 2017 | 2017 | Q3 |
| Q2 2017 | $18,758,000 | $5,639,000 | +$96,163,000 | +94% | 01 Apr 2017 | 30 Jun 2017 | 10-Q | 03 Aug 2018 | 2018 | Q2 |
| Q1 2017 | $114,921,000 | $6,438,000 | +$28,445,000 | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 04 May 2018 | 2018 | Q1 | |
| Q4 2016 | $143,366,000 | $3,217,000 | +$11,093,000 | +78% | 01 Oct 2016 | 31 Dec 2016 | 10-K | 16 Mar 2018 | 2017 | FY |
| Q3 2016 | $154,459,000 | $16,340,000 | +$9,776,000 | +37% | 01 Jul 2016 | 30 Sep 2016 | 10-Q | 02 Nov 2017 | 2017 | Q3 |
| Q2 2016 | $164,235,000 | $101,802,000 | -$76,731,000 | -306% | 01 Apr 2016 | 30 Jun 2016 | 10-Q | 03 Aug 2017 | 2017 | Q2 |
| Q1 2016 | $87,504,000 | $22,007,000 | -$182,096,000 | -114% | 01 Jan 2016 | 31 Mar 2016 | 10-Q | 04 May 2017 | 2017 | Q1 |
| Q4 2015 | $94,592,000 | $14,310,000 | -$8,320,000 | -139% | 01 Oct 2015 | 31 Dec 2015 | 10-K | 16 Mar 2018 | 2017 | FY |
| Q3 2015 | $102,912,000 | $26,116,000 | -$19,026,000 | -268% | 01 Jul 2015 | 30 Sep 2015 | 10-Q | 03 Nov 2016 | 2016 | Q3 |
| Q2 2015 | $121,938,000 | $25,071,000 | +$24,019,000 | +49% | 01 Apr 2015 | 30 Jun 2015 | 10-Q | 04 Aug 2016 | 2016 | Q2 |
| Q1 2015 | $97,919,000 | $160,089,000 | +$94,449,000 | +144% | 01 Jan 2015 | 31 Mar 2015 | 10-Q | 04 May 2016 | 2016 | Q1 |
| Q4 2014 | $3,470,000 | $5,990,000 | 01 Oct 2014 | 31 Dec 2014 | 10-K | 22 Mar 2017 | 2016 | FY | ||
| Q3 2014 | $7,090,000 | 01 Jul 2014 | 30 Sep 2014 | 10-Q | 05 Nov 2015 | 2015 | Q3 | |||
| Q2 2014 | $49,090,000 | -$46,193,000 | -1595% | 01 Apr 2014 | 30 Jun 2014 | 10-Q | 07 Aug 2015 | 2015 | Q2 | |
| Q1 2014 | $65,640,000 | +$69,542,000 | 01 Jan 2014 | 31 Mar 2014 | 10-Q | 06 May 2015 | 2015 | Q1 | ||
| Q2 2013 | $2,897,000 | 01 Apr 2013 | 30 Jun 2013 | 10-Q | 07 Nov 2014 | 2014 | Q3 | |||
| Q1 2013 | $3,902,000 | 01 Jan 2013 | 31 Mar 2013 | 10-Q | 14 May 2014 | 2014 | Q1 |
Arbutus Biopharma Corp Annual Cash and Cash Equivalents, Period Increase (Decrease) (CAD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2012 | CA$37,601,384 | +CA$40,763,260 | 01 Jan 2012 | 31 Dec 2012 | 20-F | 27 Mar 2013 | 2012 | FY | |
| 2011 | CA$3,161,876 | +CA$8,889,854 | +74% | 01 Jan 2011 | 31 Dec 2011 | 20-F | 27 Mar 2013 | 2012 | FY |
| 2010 | CA$12,051,730 | 01 Jan 2010 | 31 Dec 2010 | 20-F | 27 Mar 2013 | 2012 | FY |
* marks a reported value that did not pass the local value check.